Robert Popovian 02:23 Well, first and foremost, the reason I authored a paper is because frankly, if you dont have transparency in the marketplace, and you dont have accurate collection of information and data, youre going to make poor policy decisions
Researchers are now trying to determine whether the same protective effects seen in preclinical models may translate into meaningful outcomes for patients
For instance, liposomal carriers have been developed to encapsulate exenatide and liraglutide, demonstrating improved stability and sustained release upon subcutaneous or intranasal administration
Semaglutide is contraindicated in pregnancy, and breastfeeding is not recommended
We understand some people may be hesitant to try a suppository
Various clinical trials have reported these findings, which are discussed further in our study [11-14]